- Home
- MAKO vs ACHV Comparison
MAKO vs ACHV Comparison
Compare MAKO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAKO | ACHV |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.7M | 618.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MAKO | ACHV |
|---|---|---|
| Price | $6.98 | $5.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 105.1K | ★ 1.6M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.58 | $2.38 |
| 52 Week High | $8.17 | $7.11 |
Technical Indicators
Market Signals| Indicator | MAKO | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 50.45 |
| Support Level | $6.58 | $5.76 |
| Resistance Level | $7.60 | $7.11 |
| Average True Range (ATR) | 0.32 | 0.39 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 39.68 | 33.14 |
Price Performance
Historical ComparisonAbout MAKO Mako Mining Corp Common Stock
Mako Mining Corp is a gold mining, development, and exploration firm. The companies primary asset is the San Albino mine, an open-pit mine located in Nicaragua. In addition to its mining operation, the company continues to explore its other concessions in Nicaragua and Guyana.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.